I

Intensity Therapeutics Inc
NASDAQ:INTS

Watchlist Manager
Intensity Therapeutics Inc
NASDAQ:INTS
Watchlist
Price: 0.338 USD 4% Market Closed
Market Cap: 8.8m USD

Relative Value

There is not enough data to reliably calculate the relative value of INTS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INTS Relative Value
Base Case
Not Available
I
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.6
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-7.1
Industry
24.2
Forward
-0.4
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-8.8
Industry
20.3
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-8.8
Industry
22.9
vs History
33
vs Industry
8
Median 3Y
17
Median 5Y
17
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.7
Industry
5.1
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.7
Industry
5.1
Forward
-0.5
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-8.2
Industry
5.7
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-8.2
Industry
4.2
vs History
70
vs Industry
8
Median 3Y
44.5
Median 5Y
44.5
Industry
5.2

Multiples Across Competitors

INTS Competitors Multiples
Intensity Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Intensity Therapeutics Inc
NASDAQ:INTS
8.8m USD 0 -0.6 -0.5 -0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 214 626.8 -162 617 -197 469 -195 215.6
US
Abbvie Inc
NYSE:ABBV
333B USD 5.8 80.1 15.3 22.6
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD 374 305.7 -13 141.6 -13 213.5 -13 207.5
US
Amgen Inc
NASDAQ:AMGN
162B USD 4.7 27.3 14.6 24.1
US
Gilead Sciences Inc
NASDAQ:GILD
140.7B USD 4.9 23.6 10.2 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.4B USD 10.7 -119.7 25.5 26.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 059 -525.4 -572.1 -556.9
AU
CSL Ltd
ASX:CSL
130.8B AUD 5.6 31.1 19 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD 4.3 13.4 12 13.5
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.5 -59.1
P/S Multiple
Revenue Growth P/S to Growth
US
I
Intensity Therapeutics Inc
NASDAQ:INTS
Average P/S: 3 459 104.7
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 214 626.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
374 305.7
140%
2 673.6
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.7
10%
1.1
US
E
Epizyme Inc
F:EPE
2 059
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
S
Seagen Inc
F:SGT
19.8
30%
0.7
P/E Multiple
Earnings Growth PEG
US
I
Intensity Therapeutics Inc
NASDAQ:INTS
Average P/E: 35.1
Negative Multiple: -0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 617 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.1
88%
0.9
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 141.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
27.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.4 N/A N/A
AU
CSL Ltd
ASX:CSL
31.1
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
I
Intensity Therapeutics Inc
NASDAQ:INTS
Average EV/EBITDA: 16.1
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 469 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.6
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.1 N/A N/A
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
I
Intensity Therapeutics Inc
NASDAQ:INTS
Average EV/EBIT: 20.8
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 215.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.1
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.9 N/A N/A
AU
CSL Ltd
ASX:CSL
23.7
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.1 N/A N/A